Act Methylphenidate ER 18 mg (Methylphenidate Hydrochloride TABLET (EXTENDED-RELEASE)) 18 MG

ACT Methylphenidate ER 18 MG extended-release tablets are a prescription medication used to manage ADHD symptoms. This extended-release formulation provides long-lasting effects for better symptom control.

Strength

18 MG

Pack Size

100

Manufacturer / TM Owner

TEVA CANADA LIMITED

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

ACT Methylphenidate ER 18 MG is primarily used to treat attention deficit hyperactivity disorder (ADHD). It helps improve focus, reduce impulsivity, and manage hyperactivity. This medication is designed for extended-release, providing symptom control throughout the day.

Side Effects

Common effects of ACT Methylphenidate ER 18 MG may include increased alertness, improved concentration, and reduced hyperactivity. Some users may experience mild side effects such as decreased appetite, trouble sleeping, or dry mouth.

Precautions & Warnings

ACT Methylphenidate ER 18 MG should be taken as directed by a healthcare provider. It is important to follow the prescribed dosage and administration instructions. This medication should be stored securely to prevent misuse.

Avoid Interactions

ACT Methylphenidate ER 18 MG may interact with certain medications, including MAO inhibitors, antidepressants, and blood pressure medications. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions.

Frequently Asked Questions

ACT Methylphenidate ER 18 MG is used to treat attention deficit hyperactivity disorder (ADHD) by improving focus and reducing hyperactivity.

ACT Methylphenidate ER 18 MG should be taken orally, typically once daily in the morning, as directed by a healthcare provider.

Common side effects may include decreased appetite, trouble sleeping, and dry mouth.

It is important to consult a healthcare provider before taking ACT Methylphenidate ER 18 MG with other medications to avoid potential interactions.

Long-term use of ACT Methylphenidate ER 18 MG should be monitored by a healthcare provider to ensure safety and effectiveness.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.